Andra AP fonden Grows Stake in DaVita Inc. $DVA

Andra AP fonden increased its position in shares of DaVita Inc. (NYSE:DVA) by 2.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 236,584 shares of the company’s stock after purchasing an additional 5,400 shares during the quarter. Andra AP fonden owned approximately 0.34% of DaVita worth $31,435,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of DVA. NewEdge Advisors LLC grew its holdings in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of DaVita by 4.0% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 113,503 shares of the company’s stock valued at $16,169,000 after acquiring an additional 4,404 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of DaVita in the 2nd quarter valued at $1,243,000. Finally, Teacher Retirement System of Texas lifted its holdings in shares of DaVita by 1.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after purchasing an additional 94 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Up 2.2%

Shares of NYSE DVA opened at $152.77 on Friday. The firm has a market cap of $10.21 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.52 and a beta of 0.99. The business has a 50 day moving average price of $123.36 and a two-hundred day moving average price of $125.82. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $157.12.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.16. The company had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the business earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DVA has been the topic of several research reports. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. UBS Group boosted their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Barclays raised their price objective on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, DaVita has an average rating of “Hold” and an average price target of $155.80.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.